[18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer

Metastatic Prostate Cancer Clinical Trial

Official title:

A Phase 1 Study of [18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04528199
• Other study ID #: J19145
• Secondary ID: IRB00231620
• Status: Terminated
• Phase: Phase 1
• Start date: February 1, 2021
• Est. completion date: April 21, 2023

Study information

• Verified date: January 2024
• Source: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is an open label, single-arm study designed to evaluate the safety and diagnostic performance of [18F]FLOR (FC303) PET/CT imaging to determine the presence or absence of metastatic prostate cancer. .

Description:

This research is being done to determine whether the radioactive compound called [18F]FLOR (FC303) is safe and well-tolerated in patients with metastatic prostate cancer.

Participants in this study will have tests, exams and procedures that are for study purposes. Participants will be in this study up to one month which will include up to three clinic visits.

Eligible patients diagnosed with metastatic prostate cancer will undergo a [18F]FLOR (FC303) PET-CT scan. This is the imaging procedure to assess where [18F]FLOR (FC303) has accumulated in the body.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 8
• Est. completion date: April 21, 2023
• Est. primary completion date: April 21, 2023
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Males =18 years of age.

• Subjects provide signed informed consent and confirm that they are able and willing to comply with all protocol requirements.

• Histologically confirmed adenocarcinoma of the prostate.

• Radiologic evidence of local recurrence or new or progressive metastatic disease demonstrated on anatomical imaging (CT, or MRI), or whole-body bone scan within 4 weeks of Day 1.

• At least 2 weeks must have elapsed between last anti-cancer treatment administration and the imaging day. Imaging day will be scheduled before initiation of new systemic therapy for recurrent and/or progressive metastatic disease

• Screening clinical laboratory values within normal limits or judged not clinically significant by the investigator.

Exclusion Criteria:

• Subjects administered any radioisotope within five physical half-lives prior to study drug injection.

• Subjects with any medical condition or other circumstances that, in the opinion of the investigator, compromise obtaining reliable data, achieving study objectives, or completion.

Related Conditions & MeSH terms

• Metastatic Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• [18F]FLOR (FC303) Injection
Single dose of 10 ±1 millicurie (mCi) of [18F]FLOR (FC303) injection followed by the PET/CT scan.

Locations

Country	Name	City	State
United States	Johns Hopkins University	Baltimore	Maryland

Sponsors (2)

Lead Sponsor	Collaborator
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	FutureChem

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of study drug emergent adverse events	Incidence of study drug emergent adverse events will be assessed.	Up to 10 days post-study drug dosing